Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Bladder Cancer Treatments Continue to Evolve

December 9th 2016

The treatment landscape of bladder cancer drastically changed this spring with the approval of an immunotherapy agent, and will continue to shift in the months and years to come.

Popular Bladder Cancer Drug Production Halts, Worrying Patients, Physicians

December 1st 2016

One company's production of a popular bladder cancer therapy is set to halt by mid-2017, generating worries from patients and oncologists that there will be a shortage.

Immunotherapy Combination Shows Promise in Bladder Cancer

December 1st 2016

The combination of Opdivo and Yervoy is showing promise in the treatment of bladder cancer, according to a recent study.

Leveling the Playing Field for LGBT Patients

December 1st 2016

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

Experts Discuss Immunotherapy's Role in the Shifting Landscape in Solid Tumors

November 30th 2016

A panel of experts recently discussed the evolving field of immunotherapy for solid tumor types.

Immunotherapy Will Be the Norm in Bladder Cancer Care

November 22nd 2016

When it comes to bladder cancer, PD-1 and PD-L1 agents will become the new mainstay, says Jonathan E. Rosenberg, M.D.

Anti-PD-1 Agent Improves Overall Survival in Bladder Cancer

November 15th 2016

According to results from a recent study, Keytruda had longer overall survival (OS) when compared to chemotherapy for patients with bladder cancer.

Using Biomarkers in Bladder Cancer Diagnosis and Monitoring

November 9th 2016

Biomarkers have value in the diagnosis and monitoring of bladder cancer, but their use is still being perfected.

Exploring Immunotherapy's Future in Bladder Cancer

November 7th 2016

Geoffrey Sklar, M.D. talks about the successes of immunotherapy agents like Opdivo, and where this research is moving in the field of bladder cancer.

Immunotherapy Agent Shows Promise in Advanced Bladder Cancer

November 2nd 2016

Opdivo had positive results in patients with advanced bladder cancer according to findings from the CheckMate-275 trial.

8 Questions With a Physician: Immunotherapy in Genitourinary Cancers

October 3rd 2016

There have been some exciting advances in using immunotherapy to treat GU malignancies such as kidney and bladder cancer. CURE sat down with Elizabeth Plimack, M.D. to discuss them.

Matthew Galsky Gives an Overview of Bladder Cancer

September 30th 2016

Matthew Galsky, M.D., professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the different stages and curability of bladder cancer.

Cystectomy to Treat Bladder Cancer: It's Complicated

September 28th 2016

Treating bladder cancer with a cystectomy may bring about some complicated side effects. Here are some resources to help.

Honing in on Bladder Cancer: Key Facts

September 28th 2016

CURE gathered some need-to-know facts about bladder cancer, the sixth most common cancer.

From Rags to Riches: Bladder Cancer Research Rife With New Approaches

September 27th 2016

For decades, research into bladder cancer treatments was stagnant, but now science has moved into a period rife with new approaches — immunotherapy chief among them.

Creating a Diversion: Life After Cystectomy for Bladder Cancer

September 22nd 2016

After the bladder is surgically removed and the urinary system diverted, most can return to their usual activities.

3 Questions: The Impact of Tecentriq to Treat Patients With Advanced Bladder Cancer

September 19th 2016

Tecentriq (atezolizumab) has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

Setback for Novel Agent to Treat Subset of Patients With Bladder Cancer

September 19th 2016

The FDA voted against approving Qapzola for treatment of some patients with bladder cancer.

BCAN Focused on Building a High-Energy Community for Bladder Cancer

September 16th 2016

Educate, engage and energize — those are the three main verbs and goals of the Bladder Cancer Advocacy Network’s (BCAN) first ever leadership summit.

6 Questions With a Physician: Tecentriq, Immunotherapies for Bladder Cancer

August 22nd 2016

After a long lapse in advancements for bladder cancer, the approval of Tecentriq is changing the field.

Gaining a Better Understanding of Immunotherapy in Bladder Cancer

August 17th 2016

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

Expert Discusses Changing Field of Immunotherapy to Treat Genitourinary Cancers

August 13th 2016

Randy F. Sweis talks to CURE about the future of treatment for GU cancers.

Improving Care for Patients With Muscle-Invasive Bladder Cancer

July 20th 2016

CURE spoke with Stanley Yap about how physicians can improve care for patients with muscle-invasive bladder cancer.

Early Immunotherapy Data: 8 Questions With a Bladder Cancer Expert

July 19th 2016

The FDA granted the PD-L1 inhibitor Tecentriq an accelerated approval in May 2016 as a treatment for patients with locally advanced or metastatic urothelial carcinoma, following encouraging results of the phase 2 IMvigor 210 study.

Opdivo Making Strides in Advanced Bladder Cancer

July 7th 2016

“Urothelial cancer is a common type of bladder cancer where patients experience high rates of recurrence and remains an area where new treatment approaches are needed, further underscoring the importance of this designation for Opdivo,” said Jean Viallet.

Large Analysis Finds Men Live Longer With Bladder Cancer Than Women

June 23rd 2016

A large study found that women with bladder cancer generally have lower overall survival rates than their male counterparts.

Early Trial Data Provide Reason for Hope in Bladder Cancer

June 15th 2016

A recent phase 1 study shows promise for the treatment of bladder cancer.

Tecentriq Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Tecentriq is showing reduction in tumor size for patients with metastatic urothelial carcinoma, according to a phase 2 study.

FDA Approves Tecentriq for Metastatic Bladder Cancer

May 19th 2016

Based on data from a phase 2 study, Tecentriq (atezolizumab), a PD-L1 inhibitor, was granted an accelerated approval for patients with locally advanced or metastatic urothelial carcinoma.

Arsenic in New England Well Water Suspected Root of 50-Year Bladder Cancer Rise

May 18th 2016

Researchers are identifying a link between drinking well water from the North East and developing bladder cancer.

NEXT PAGE
PREVIOUS PAGE